Educational pharmacology review updated 10 November 2026. This information does not replace a patient-specific clinical evaluation or current local prescribing guidance.
Overview
Opioids are analgesics for selected moderate-to-severe acute pain, cancer-related pain and palliative care, and for carefully selected chronic pain cases when benefits outweigh harms. For many common subacute and chronic pain conditions, nonopioid and nonpharmacologic treatments are preferred. Respiratory depression, dependence and overdose are central safety concerns [1,2].
Classes and receptor mechanisms
- Full μ-opioid agonists: morphine, oxycodone, hydromorphone, fentanyl and methadone.
- Partial μ-opioid agonist: buprenorphine has high receptor affinity and a ceiling effect on some respiratory responses, but overdose can still occur, especially with sedatives.
- Mixed opioid receptor agents: nalbuphine has κ agonist and μ antagonist activity; butorphanol has mixed activity.
- Antagonists: naloxone and naltrexone block opioid receptors and do not have routine partial agonist analgesic effects.
- Dual-action analgesics: tramadol has weak μ activity plus serotonin/norepinephrine reuptake effects; tapentadol has μ agonism plus norepinephrine reuptake inhibition [1].
Pharmacodynamics and PK
μ receptors couple to Gi/o proteins, inhibit adenylyl cyclase, reduce presynaptic calcium entry and increase potassium conductance, suppressing neuronal transmission. Morphine forms glucuronides, including renally cleared active metabolites; kidney impairment can increase adverse effects. Codeine requires CYP2D6 conversion to morphine, leading to variable efficacy and toxicity. Fentanyl is highly lipophilic; transdermal delivery is for appropriately opioid-tolerant patients, not rapid treatment of opioid-naive acute pain [1].
Evidence-based prescribing
The CDC 2022 guideline calls for setting realistic pain/function goals, immediate-release rather than extended-release/long-acting opioids when starting opioid therapy, careful reassessment and individualized dose decisions. Avoid abrupt discontinuation in physically dependent patients except in urgent safety circumstances; collaborate on gradual tapering when indicated. Check other sedatives, sleep apnea, substance use disorder and prior overdose risk, and offer naloxone to higher-risk patients [2].
Toxicity, interactions and reversal
Respiratory depression and reduced consciousness require emergency response, ventilation support and naloxone with repeat dosing if necessary. Combining opioids with benzodiazepines, alcohol or gabapentinoids increases sedation and respiratory risk. Methadone can cause QT prolongation. Tramadol may cause seizures or serotonin toxicity with serotonergic medicines; opioids can cause constipation, nausea, urinary retention and endocrine effects [1,2].
Dependence and special populations
Physical dependence and tolerance may develop even with correct medical use; they are not equivalent to opioid use disorder. Patients with opioid use disorder should be offered evidence-based treatments such as buprenorphine or methadone, rather than being denied appropriate care. Pregnancy, pediatric use, older age and renal impairment require drug- and setting-specific safeguards [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep. 2022;71(3):1–95. doi:10.15585/mmwr.rr7103a1. Available from: https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.